Skip to main content

Advertisement

Table 1 Baseline demographics

From: A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer’s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil

  SAM-760 30 mg QD (n = 92) Placebo (n = 94)
Male, n (%) 46 (50.0) 39 (41.5)
Mean age, years (SD) 76.0 (8.0) 75.9 (7.5)
Mean weight, kg (SD) 72.4 (13.3) 70.8 (15.4)
Mean body mass index, kg/m2 (SD) 26.8 (4.6) 26.8 (4.3)
Mean height, cm (SD) 164.4 (9.6) 161.8 (11.1)
Mean duration since AD diagnosis, years 2.8 2.9
MMSE score mild (20–24), n (%) 53 (57.6) 47 (50)
MMSE score moderate (10–19), n (%) 39 (42.4) 47 (50)
Mean total MMSE score (SD) 19.7 (4.2) 19.6 (4.0)
Mean ADAS-cog13 score (SD) 34.9 (14.8) 33.2 (12.7)
Mean NPI score (SD) 21.1 (12.4) 21.8 (11.9)
Mean ADAS-cog11 score (SD) 25.7 (12.4) 24.1 (10.6)
Mean ADCS-ADL score (SD) 57.8 (13.7) 57.7 (15.7)
Mean CGI-I score (SD) 3.8 (0.8) 3.6 (0.6)
Mean CSDD score (SD) 5.9 (4.3) 5.3 (3.6)
Mean executive function composite score (SD)a −0.1 (0.1) 0.1 (0.1)
ApoE4 genotype, n (%)   
 E2/E4 2 (2.2) 2 (2.2)
 E3/E4 37 (40.1) 41 (44.6)
 E4/E4 7 (7.7) 4 (4.4)
  1. aComposite of Category Fluency Test and Controlled Oral Word Association Test
  2. AD Alzheimer’s disease, ADAS-cog13/11 Alzheimer’s Disease Assessment Scale-cognitive subscale, ADCS-ADL Alzheimer’s Disease Cooperative Study-Activities of Daily Living, CGI-I Clinician’s Global Impression of Improvement, CSDD Cornell Scale for Depression in Dementia, CFT Category Fluency Test (executive function), COWAT Controlled Oral Word Association Test, MMSE Mini-Mental State Examination, NPI Neuropsychiatric Inventory, QD once daily, SD standard deviation